Udier, who holds a PhD in Organic Chemistry from Yale University, joined Nouscom as Chief Operating Officer in 2016. Previously, she held the position of Operating Principal at Versant Ventures. Before that, she was the Global Head of Neurodegeneration at Novartis, and worked in the healthcare sector of McKinsey & Company in Chicago.

“The board has been impressed with the operational and strategic achievements made since Marina was appointed CEO on an interim basis in May 2019,” said Guido Magni, Chairman of the Board of Nouscom. “The Board has therefore decided to make Marina’s appointment as CEO permanent and has confidence in her ability to lead the business into its next chapter.”

Another addition to the Nouscom team is Patricia Delaite, who was named Chief Medical Officer. Delaite joins from AMAL Therapeutics, which was acquired by Boehringer Ingelheim last year.